ArticleBMC medicine2024
Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK.
Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Impact of frailty on overall survival and complications in patients with prostate cancer: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- Spatiotemporal patterns and clustering of prostate cancer incidence in China: a Bayesian modeling study of cancer registry data.BMC public health · 2026Article
- Disparities in prostate cancer outcomes between First Nations and Non-First Nations men in Canada-Cohort study.Lancet regional health. Americas · 2026Article
- Prognostic biomarkers and regulatory mechanisms associated with lysine β-hydroxybutyrylation modification in prostate cancer.Frontiers in molecular biosciences · 2026Article
- Barriers and facilitators to prostate cancer healthcare in Black men in the UK: from diagnosis to survivorship.Journal of cancer survivorship : research and practice · 2025Article
- Anaemia, ethnicity, and cancer incidence: a retrospective cohort study in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Calcium and Albumin Blood Tests, Ethnicity, and Cancer Incidence in Primary Care in the UK.Cancers · 2025Article
- Use of Systemic Glucocorticoids and Risk of Prostate Adenocarcinoma: Evidence From a Danish Population-Based Case-Control Study.Cancer medicine · 2025Article
- AMACR is a highly sensitive and specific immunohistochemical marker for diagnosing prostate cancer on biopsy: a systematic review and meta-analysis.Journal of pathology and translational medicine · 2025Article
- Global research trends on the links between prostate cancer and postoperative urinary incontinence between 2014 and 2024: a bibliometrics and visualized study.Discover oncology · 2025Article
- Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.Nature reviews. Urology · 2025Review
- Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients.Cancer management and research · 2025Article
- Variations in the Use of Faecal Immunochemical Testing (FIT) in Primary Care in England: A Population-Based Cohort of 531,735 FITs from 495,121 Patients Between 2019 and 2023.Clinical epidemiology · 2025Article
- PSMA-based theranostics in diagnosing and treating prostate cancer in the Asian male population: a narrative review.Frontiers in oncology · 2025Review
- Health inequalities in cancer care: a literature review of pathways to diagnosis in the United Kingdom.EClinicalMedicine · 2024Review
- Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments.Cancer reports (Hoboken, N.J.) · 2024Review
- Review
- The diagnostic performance of CA-125 for the detection of ovarian cancer in women from different ethnic groups: a cohort study of English primary care data.Journal of ovarian research · 2024Article
- A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease.JCO precision oncology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBlack men have higher prostate-specific antigen (PSA) levels and higher prostate cancer incidence and mortality than White men, while Asian men tend to have lower prostate cancer incidence and mortality than White men. Much of the evidence comes from the USA, and information from UK populations is limited.
methodsThis retrospective cohort study used data on patients registered at general practices in England contributing to the Clinical Practice Research Datalink (CPRD) Aurum dataset. Those eligible were men aged 40 and over with a record of ethnicity and a PSA test result recorded between 2010 and 2017 with no prior cancer diagnosis. The aim was to assess the incidence of prostate cancer following a raised PSA test result in men from different ethnic groups. Additionally, incidence of advanced prostate cancer was investigated. Cancer incidence was estimated from multi-level logistic regression models adjusting for potential confounding factors.
results730,515 men with a PSA test were included (88.9% White). Black men and men with mixed ethnicity had higher PSA values, particularly for those aged above 60 years. In the year following a raised PSA result (using age-specific thresholds), Black men had the highest prostate cancer incidence at 24.7% (95% CI 23.3%, 26.2%); Asian men had the lowest at 13.4% (12.2%, 14.7%); incidence for White men was 19.8% (19.4%, 20.2%). The peak incidence of prostate cancer for all groups was in men aged 70-79. Incidence of prostate cancer diagnosed at an advanced stage was similar between Black and White men.
conclusionsMore prostate cancer was diagnosed in Black men with a raised PSA result, but rates of advanced prostate cancer were not higher in this group. In this large primary care-based cohort, the incidence of prostate cancer in men with elevated PSA levels increases with increasing age, even when using age-adjusted thresholds, with Black men significantly more likely to be diagnosed compared to White or Asian men. The incidence of advanced stage prostate cancer at diagnosis was similar for Black and White men with a raised PSA result, but lower for Asian men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.